Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051506 · ClinicalTrials.gov registry record · Phase 2
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00051506: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00051506 is a Phase 2 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051506, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG ALIMTA
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00051506 record still lists
NCT00051506 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00051506 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00051506 about?
NCT00051506 is a clinical study titled "ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.". The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
What is the current status of trial NCT00051506?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00051506?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), ALIMTA (DRUG).
Who is sponsoring clinical trial NCT00051506?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.